mRNA Vaccine Development Against Human Avian Influenza (H5N1):
A new initiative to develop and distribute mRNA vaccines for human avian influenza (H5N1) in low- and middle-income countries (LMICs), in collaboration with the World Health Organization (WHO) and the Medicines Patent Pool (MPP).
- The project is part of the mRNA Technology Transfer Programme, established in 2021 to enhance vaccine production capacity in LMICs.
- Once successful, the knowledge and materials will be shared with other manufacturers to expedite vaccine development and strengthen pandemic preparedness.
- The initiative aligns with ongoing efforts to improve the sharing of influenza viruses and vaccine access under the Pandemic Influenza Preparedness Framework.
- The mRNA Technology Transfer Programme has already developed a platform for COVID-19 vaccine candidates, which is now being adapted for other diseases, enhancing global vaccine equity.
